Candel Therapeutics Inc.

CADL | NASDAQ

Price Alert Chart Builder DCF Calculator

$11.73

+$0.52 (+4.64%)

Sep 22, 2026, 12:48 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+4.64%

(1D)

Rating

Updated: Aug 28, 2026

23.5

Fundamentals Weak

Market Sentiment Bullish

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $859.46M

1D Range

11.19 11.75

52W Range

4.35 14

Valuation (TTM)

PE -7.95

PB 6.51

EV/EBITDA -11.07

Valuation (NTM)

Forward PE N/A

Forward PEG 0.38

Price Target $22.50

Cash Flow

FCF Yield -7.0%

SBC Adj. FCF Yield -7.8%

SBC Impact -11.8%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | -83.3%

Dil EPS 3Y | 5Y 11.4% | -6.5%

FCF 3Y | 5Y -33.3% | -14.1%

Returns

ROA -42.5%

ROE -89.4%

ROIC -36.7%

Financial Health

Net Cash

$153.73M

Current Ratio 16.09

Interest Coverage -15.26

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-...

Sector Healthcare

Industry Biotechnology

Employees 55

IPO Date Jul 26, 2021

Website www.candeltx.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$22.50

Upside

+91.82%

Buy (5)

Hold (1)

Sell (0)

Analyst Details ➞